Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Breast Neoplasms
  • Drug Resistance, Neoplasm
  • Receptor, ErbB-2

abstract

  • In this pooled analysis of 307 patients with MBC, individuals who did not achieve a significant decline (>or=20%) in serum HER-2/neu levels had decreased benefit from trastuzumab-based therapy, and these patients should be considered for clinical trials evaluating additional HER-2/neu-targeted interventions.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.23689

PubMed ID

  • 18661530

Additional Document Info

start page

  • 1294

end page

  • 301

volume

  • 113

number

  • 6